FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157978633> ?p ?o ?g. }

• W3157978633 endingPage "705" @default.
• W3157978633 startingPage "705" @default.
• W3157978633 abstract "Small cell lung cancer (SCLC) is a very aggressive and proliferative disease, with little progress being having made for its treatment in decades. Our goal was to evaluate the effect of immune checkpoint inhibitors (ICIs) and identify optimal first-line interventions for the treatment of SCLC.A systematic literature search of the Cochrane Library, PubMed and oncology conference proceedings were conducted. Randomized trials evaluating ICIs for SCLC were included. We use the risk of bias tool in RevMan 5.3 to assess the quality of studies. We used Stata version 15.0 to carry out data direct comparison and R version 4.0.2 to conduct the Bayesian network analysis.A total of 16 relevant clinical trials comprising 4,476 patients were included. We found the magnitude of efficacy for ICIs as first-line therapy conferred a statistically significant benefit in overall survival (OS) and progression-free survival compared to chemotherapy alone. The results were 0.82 (95% CI, 0.76-0.89, P<0.001) and 0.80 (95% CI, 0.74-0.86, P<0.001). For objective response rate (ORR), the result (1.13, 95% CI, 0.97-1.31, P=0.109) was not significant. In the second-line and maintenance treatment, no additional benefit was observed. With regard to safety, results showed that for all grades of AEs and grades 3-4 AEs, the pooled results were 1.36 (95% CI: 0.50-3.70; P=0.543) and 1.35 (95% CI: 0.58-3.15; P=0.484) respectively. In addition, the indirect comparison results showed that nivolumab combined with chemotherapy led to the most significant improvement in OS, while durvalumab combined with chemotherapy was a more efficacious therapy for improving ORR compared with the other interventions; the probability were the best treatments was 73.93% and 81% respectively.Our results showed ICIs combined with etoposide and platinum-based drugs as first-line treatment of SCLC have benefits for patients and there was no evidence of a significant difference in efficacy among the different ICI drugs used for the first-line therapy. As for toxicity, the ICIs did not increase the frequency AEs for patients. However, as some studies are ongoing and the full data have still not been reported, our conclusions may not be completely representative." @default.
• W3157978633 created "2021-05-10" @default.
• W3157978633 creator A5003091315 @default.
• W3157978633 creator A5013700595 @default.
• W3157978633 creator A5024327669 @default.
• W3157978633 creator A5032477448 @default.
• W3157978633 creator A5043336061 @default.
• W3157978633 creator A5045094860 @default.
• W3157978633 creator A5052547773 @default.
• W3157978633 creator A5066373238 @default.
• W3157978633 creator A5075120323 @default.
• W3157978633 date "2021-04-01" @default.
• W3157978633 modified "2023-10-16" @default.
• W3157978633 title "Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis" @default.
• W3157978633 cites W1967385770 @default.
• W3157978633 cites W1971181039 @default.
• W3157978633 cites W2003195799 @default.
• W3157978633 cites W2019023200 @default.
• W3157978633 cites W2020917220 @default.
• W3157978633 cites W2029854747 @default.
• W3157978633 cites W2058264985 @default.
• W3157978633 cites W2066671159 @default.
• W3157978633 cites W2066753614 @default.
• W3157978633 cites W2072818007 @default.
• W3157978633 cites W2074552727 @default.
• W3157978633 cites W2075535893 @default.
• W3157978633 cites W2098923148 @default.
• W3157978633 cites W2107328434 @default.
• W3157978633 cites W2123589978 @default.
• W3157978633 cites W2125435699 @default.
• W3157978633 cites W2127363643 @default.
• W3157978633 cites W2144625636 @default.
• W3157978633 cites W2150529573 @default.
• W3157978633 cites W2152061559 @default.
• W3157978633 cites W2169884947 @default.
• W3157978633 cites W2285109017 @default.
• W3157978633 cites W2312312686 @default.
• W3157978633 cites W2418354692 @default.
• W3157978633 cites W2480201404 @default.
• W3157978633 cites W2560367415 @default.
• W3157978633 cites W2576440140 @default.
• W3157978633 cites W2576935917 @default.
• W3157978633 cites W2588681363 @default.
• W3157978633 cites W2592145077 @default.
• W3157978633 cites W2595863515 @default.
• W3157978633 cites W2768429453 @default.
• W3157978633 cites W2797855256 @default.
• W3157978633 cites W2800160190 @default.
• W3157978633 cites W2889317689 @default.
• W3157978633 cites W2890799019 @default.
• W3157978633 cites W2893960509 @default.
• W3157978633 cites W2908914600 @default.
• W3157978633 cites W2942616749 @default.
• W3157978633 cites W2945928820 @default.
• W3157978633 cites W2952275958 @default.
• W3157978633 cites W2965684837 @default.
• W3157978633 cites W2973098277 @default.
• W3157978633 cites W2977392388 @default.
• W3157978633 cites W2980593108 @default.
• W3157978633 cites W3013383466 @default.
• W3157978633 cites W3024852848 @default.
• W3157978633 cites W3030178583 @default.
• W3157978633 cites W3047718208 @default.
• W3157978633 cites W3110002524 @default.
• W3157978633 cites W4238709685 @default.
• W3157978633 doi "https://doi.org/10.21037/atm-21-1423" @default.
• W3157978633 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8106042" @default.
• W3157978633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33987403" @default.
• W3157978633 hasPublicationYear "2021" @default.
• W3157978633 type Work @default.
• W3157978633 sameAs 3157978633 @default.
• W3157978633 citedByCount "6" @default.
• W3157978633 countsByYear W31579786332021 @default.
• W3157978633 countsByYear W31579786332022 @default.
• W3157978633 countsByYear W31579786332023 @default.
• W3157978633 crossrefType "journal-article" @default.
• W3157978633 hasAuthorship W3157978633A5003091315 @default.
• W3157978633 hasAuthorship W3157978633A5013700595 @default.
• W3157978633 hasAuthorship W3157978633A5024327669 @default.
• W3157978633 hasAuthorship W3157978633A5032477448 @default.
• W3157978633 hasAuthorship W3157978633A5043336061 @default.
• W3157978633 hasAuthorship W3157978633A5045094860 @default.
• W3157978633 hasAuthorship W3157978633A5052547773 @default.
• W3157978633 hasAuthorship W3157978633A5066373238 @default.
• W3157978633 hasAuthorship W3157978633A5075120323 @default.
• W3157978633 hasBestOaLocation W31579786331 @default.
• W3157978633 hasConcept C126322002 @default.
• W3157978633 hasConcept C143998085 @default.
• W3157978633 hasConcept C168563851 @default.
• W3157978633 hasConcept C2776256026 @default.
• W3157978633 hasConcept C2776478404 @default.
• W3157978633 hasConcept C2776694085 @default.
• W3157978633 hasConcept C535046627 @default.
• W3157978633 hasConcept C71924100 @default.
• W3157978633 hasConcept C95190672 @default.
• W3157978633 hasConceptScore W3157978633C126322002 @default.
• W3157978633 hasConceptScore W3157978633C143998085 @default.
• W3157978633 hasConceptScore W3157978633C168563851 @default.

• next